Nova Eye (EYE) Summary 31 Dec 2023, page-13

Yeah I usually avoid recommending stocks to friends and family but EYE is a bit different. Here we have a company at the beginning of its growth journey, and which has already proved itself, generating 65% growth in what were most likely the most difficult market conditions to launch a new device (i.e. other companies saw revenue decline during the period). If that isn't the clearest proof that this new device is in very high demand, I don't know what is. Despite all this, it is still being valued as if it is a declining/challenged business. IMO it ticks all the boxes for me. Massive TAM, young industry, enormous growth runway, best in class products, extensive R&D pipeline, clear pathway to near term profitability, high margin and very lean business, high quality and highly experienced management team, recent insider buying and large insider ownership, founder still actively involved, strong brand and reputation, incredibly sticky customer base, ridiculously low valuation for a quality growth stock, large institutional presence in the shareholder register, active M&A in the industry. It's also healthcare which IMO is always a plus. I'm sure I missed a few... Plenty of companies I hold that have a number of these, but may lack one or another.